Back to Search
PETER FAST, M.D.
M.D.
Sports Medicine (Family Medicine) Physician
NPI: 1255699435IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine Physician
Family Medicine
Code: 207Q00000X
29225(OK)
Sports Medicine (Family Medicine) PhysicianPrimary
Family Medicine — Sports Medicine
Code: 207QS0010X
29225(OK)
Education
UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Class of 2012
Research & Publications (20)
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.
PMID 19197365·PLoS One·2009
8-other
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
PMID 19439467·J Virol·2009
8-other
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
PMID 18440674·Vaccine·2008
3-trial
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
PMID 18812202·Vaccine·2008
3-trial
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
PMID 18544020·AIDS Res Hum Retroviruses·2008
3-trial
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
PMID 18446196·PLoS One·2008
8-other
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
PMID 17250931·Vaccine·2007
4-observational
A strategy for accelerating the development of preventive AIDS vaccines.
PMID 18090273·AIDS·2007
6-review
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.
PMID 17075387·J Acquir Immune Defic Syndr·2007
8-other
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
PMID 16641265·J Virol·2006
3-trial
Recent trends in clinical trials of vaccines to prevent HIV/AIDS.
PMID 19372820·Curr Opin HIV AIDS·2006
8-other
Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
PMID 17019363·J Acquir Immune Defic Syndr·2006
8-other
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
PMID 16176847·Vaccine·2006
3-trial
Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.
PMID 15307033·Clin Infect Dis·2004
6-review
Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
PMID 14679275·JAMA·2003
6-review
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
PMID 11740317·Pediatr Infect Dis J·2001
3-trial
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
PMID 11311997·Vaccine·2001
3-trial
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
PMID 11228380·Vaccine·2001
3-trial
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
PMID 10875616·AIDS Res Hum Retroviruses·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2900 N MAIN ST STE 101
MUSKOGEE, OK 74401 - Phone
- (918) 684-2663
Quick Facts
- NPI
- 1255699435
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile